Crucell « Terug naar discussie overzicht

Boston Globe article on Crucell

6 Posts
Omlaag ↓
gogogoo 22 september 2006 12:04
25
Lid sinds: 28 feb 2006
Laatste bezoek: 10 aug 2023
Aantal posts:
6.042
Aanbevelingen:
Ontvangen: 1600
Gegeven: 808
Dutch firms to join Cambridge biotech cluster
By Jeffrey Krasner, Globe Staff | September 22, 2006

A joint biotechnology research venture by two Dutch companies is further underscoring the appeal of the Boston life-science cluster to out-of-state firms, and creating an even tighter real estate market in Cambridge's Kendall Square.

Breaking News Alerts The companies, Crucell N.V. and Royal DSM N.V., decided to lease buildings at 1 Hampshire St. after considering locations in Maryland and the Research Triangle Park in North Carolina, according to Dr. Marco Cacciuttolo, chief executive of the joint venture.

``Cambridge is the real gravitational center of biotechnology," said Cacciuttolo. ``It's really the premier location in the world to engage in these research activities."

The facility will employ about 50 people when fully staffed, he said.

In recent years, companies including Schering-Plough Corp., Akzo Nobel N.V., Novartis Pharma, and Merck & Co. Inc. have set up substantial research operations in Boston or Cambridge. They seek access to top biopharmaceutical talent; cutting-edge research from Harvard University, the Massachusetts Institute of Technology, and other schools; and the intangible advantage that comes from being surrounded by other life-science businesses.

The action isn't just limited to the Boston-Cambridge area. In June, drug giant Bristol-Myers Squibb Co. said it would build a $660 million manufacturing plant on part of the site of the former Fort Devens in central Massachusetts.

The Crucell-Royal DSM venture is called PER.C6 Development Center LLC, after a specific line of human cells that the companies are developing.

Many biotechnology companies manufacture treatments by modifying the genetic instructions in animal cells so they produce a specific protein with therapeutic properties. Often, those therapeutics are grown in cells derived from hamster ovaries.

But scientists have found that using proteins made from animal cells can cause dangerous side effects. They have attempted to make the therapeutics more ``human," with fewer characteristics of the host cell.

PER.C6 has developed a line of cells it believes will eliminate problems associated with proteins made from animal cells and plans to license the line to biotech companies.

``We want to license the cell line to everybody," said Cacciuttolo.

The venture is equally funded by the two partners. Crucell makes vaccines for two types of hepatitis, influenza, and the diseases that plague travelers, including typhoid. DSM is a sprawling enterprise that manufactures food and pharmaceutical ingredients, and chemicals for a wide variety of applications. It has 22,000 employees and annual sales of about $10 billion. Its biologics division provides manufacturing services to biotech companies.

The new venture will occupy most of the remaining space in a complex of new and existing buildings owned by Draper Laboratory. Last year Schlumberger Technology Corp. leased 190,000 square feet in the complex.

PER.C6 R&D Center is believed to be paying annual rent between $55 and $60 per square foot, and will also contribute to utility costs, real estate taxes, and building operating expenses, according to real estate brokers familiar with East Cambridge. It will receive an allowance of more than $100 per square foot from Draper to convert the bare space into laboratories and offices.

``The biotech cluster is a powerful draw," said Ryan Weber , a life-science specialist with NAI Hunneman Commercial , a real estate firm that represented PER.C6. ``This group felt they needed to be in Kendall Square."

Just two years ago, there was a 26.2 percent vacancy rate in Cambridge laboratory and research-and-development space, according to Mark J. Winters , executive director of Cushman & Wakefield of Massachusetts Inc., a real estate firm that represented Draper Laboratory. In the second quarter of this year, the vacancy rate dropped to 11.5 percent. Excluding space available through subleasing, the rate was even lower, 5.5 percent.

``The lab market has shifted from a tenant to a landlord market in a very short period of time," said Winter s .

Posted by Author: ron banged
www1.investorvillage.com/smbd.asp?mb=...
[verwijderd] 22 september 2006 12:18
1
Lid sinds: 01 jan 0001
Laatste bezoek: 01 jan 0001
Aantal posts:
0
Aanbevelingen:
Ontvangen: 0
Gegeven: 0
Gogogo, dank voor deze posting!

Dit klinkt toch prachtig:
PER.C6 Development Center LLC, Cambridge USA

En ze zijn er maar wat blij mee daar in de Boston area! Er ontstaat nu zelfs schaarste op de laboratorium/ kantorenmarkt. Crucell/DSM waren er nog net op tijd bij!!

Grtz,
ZEKER
gogogoo 22 september 2006 12:19
0
Lid sinds: 28 feb 2006
Laatste bezoek: 10 aug 2023
Aantal posts:
6.042
Aanbevelingen:
Ontvangen: 1600
Gegeven: 808
``We want to license the cell line to everybody," said Cacciuttolo.
[verwijderd] 22 september 2006 20:04
0
Lid sinds: 01 jan 0001
Laatste bezoek: 01 jan 0001
Aantal posts:
0
Aanbevelingen:
Ontvangen: 0
Gegeven: 0
Om je vingers bij af te likken gogogoo , ab!
Nog een stuk of tig AB's...en hop, op de voorpagina...we blijven werken voor onze centjes.
[verwijderd] 22 september 2006 20:12
0
Lid sinds: 01 jan 0001
Laatste bezoek: 01 jan 0001
Aantal posts:
0
Aanbevelingen:
Ontvangen: 0
Gegeven: 0
quote:

flosz schreef:

Om je vingers bij af te likken gogogoo , ab!
Nog een stuk of tig AB's...en hop, op de voorpagina...we blijven werken voor onze centjes.
Ok Flosz,

Dit prachtige bericht moet zeker op de voorpagina maar niet meer dan 22 x.
Waarom dan niet, omdat ik nog steeds wel een beetje trots ben op mijn positie van meest aanbevolen bericht.
Voelde jij dit ook zo de eerste keer......

groet,

Truco
[verwijderd] 22 september 2006 20:21
0
Lid sinds: 01 jan 0001
Laatste bezoek: 01 jan 0001
Aantal posts:
0
Aanbevelingen:
Ontvangen: 0
Gegeven: 0
quote:

truco1 schreef:

Voelde jij dit ook zo de eerste keer......
Uh nee, sorry....maar lang geleden, toen ik nog heel klein was, was ik erg blij met de plaatsing van een art.-je in de........schoolkrant!
gr.
6 Posts
Aantal posts per pagina:  20 50 100 | Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met uw e-mailadres en wachtwoord.

Direct naar Forum

Markt vandaag

AEX 874,02 0,00 0,00% 24 apr
AMX 925,76 0,00 0,00% 24 apr
ASCX 1.207,07 +3,02 +0,25% 24 apr
BEL 20 3.883,83 0,00 0,00% 24 apr
Germany40^ 18.086,70 -2,00 -0,01% 24 apr
US30^ 38.353,31 0,00 0,00% 24 apr
US500^ 5.072,39 0,00 0,00% 24 apr
Nasd100^ 17.524,13 0,00 0,00% 24 apr
Japan225^ 37.998,76 0,00 0,00% 24 apr
WTI 82,90 0,00 0,00% 24 apr
Brent 88,08 0,00 0,00% 24 apr
EUR/USD 1,0707 +0,0010 +0,09% 06:27
BTC/USD 64.558,77 -1.813,21 -2,73% 02:59
Gold spot 2.313,00 -3,11 -0,13% 06:27
#/^ Index indications calculated real time, zie disclaimer
HOGE RENDEMENTEN OP DE IEX-MODELPORTEFEUILLES > WORD NU ABONNEE EN PROFITEER VAN MAAR LIEFST 67% KORTING!

Aandelenadviezen van IEX.nl

  1. Premium
    Is Just Eat Takeaway ondergewaardeerd?
    11 apr | Analyse en Advies
  2. Premium
    Ingaan of niet op het bod op de Rabobank Certificaten?
    16 apr | Analyse en Advies
  3. Premium
    Vooruitblik: aftrap cijferseizoen, einde bankenfeestje en CVC naar het Damrak
    14 apr | Vooruitblik
  4. Premium
    Vooruitblik eerstekwartaalcijfers ASML
    12 apr | Analyse en Advies
  5. Premium
    Orderintake ASML doet even pijn, maar verandert dit iets aan de beleggingscase?
    17 apr | Analyse en Advies
Meer Aandelenadviezen ››

Stijgers & Dalers

Stijgers Laatst +/- % tijd
ASMI 590,000 +58,400 +10,99% 24 apr
BESI 139,000 +5,450 +4,08% 24 apr
RANDSTAD NV 46,470 +1,470 +3,27% 24 apr
Dalers Laatst +/- % tijd
ING 14,670 -0,930 -5,96% 24 apr
RELX 38,500 -0,800 -2,04% 24 apr
DSM FIRMENICH AG 104,000 -2,150 -2,03% 24 apr

EU stocks, real time, by Cboe Europe Ltd.; Other, Euronext & US stocks by NYSE & Cboe BZX Exchange, 15 min. delayed
#/^ Index indications calculated real time, zie disclaimer, streaming powered by: Infront